



Biotech Daily

Tuesday June 25, 2019

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: ORTHOCELL UP 11%; LBT DOWN 12%**
- * **IMMUTEP COMPLETES IMP321 AIPAC CANCER TRIAL ENROLMENT**
- * **ALTHEA PROJECT TWENTY21 FOR 20k UK MARIJUANA PATIENTS**
- * **ANTEO WORKS WITH SILICIO FERROSOLAR FOR LITHIUM BATTERIES**
- * **FACTOR FACES 2nd BOARD SPILL CALL**
- * **IMPEDIMED REQUESTS 'CAPITAL RAISING' TRADING HALT**
- * **UNISUPER TAKES 7% OF IMPEDIMED**
- * **SIMON CHAMBERLAIN REPLACES ALCIDION'S GEOFFREY ROHRSHEIM**

MARKET REPORT

The Australian stock market fell 0.11 percent on Tuesday June 25, 2019, with the ASX200 down 7.4 points to 6,658.0 points.

Nine of the Biotech Daily Top 40 stocks were up, 20 fell, seven traded unchanged and four were untraded.

Orthocell was the best, up 5.5 cents or 10.8 percent to 56.5 cents, with 8.6 million shares traded.

Actinogen climbed 10 percent; Avita was up 9.1 percent; Kazia improved 4.05 percent; Compumedics, Cynata and Opthea were up more than one percent; with Cochlear, CSL, Pro Medicus and Volpara up by less than one percent.

LBT led the falls, down 1.5 cents or 11.5 percent to 11.5 cents, with 3.7 million shares traded.

Proteomics lost 7.1 percent; Imugene and Osprey were down more than six percent; Polynovo retreated 5.5 percent; Clinuvel and Optiscan fell more than four percent; Immutep, Oncosil, Paradigm and Patrys were down more than three percent; Mesoblast, Prescient and Telix shed more than two percent; Benitec, Dimerix, Genetic Signatures and Nanosonics were down one percent or more; with Medical Developments, Neuren and Resmed down by less than one percent.

IMMUTEP

Immutep says it has enrolled all 226 patients for its phase IIb active immunotherapy paclitaxel with IMP321 (Aipac) trial for metastatic breast cancer.

Immutep said the trial enrolled patients with human epidermal receptor 2 (HER2) negative and hormone receptor (HR) positive metastatic breast cancer, who were not eligible for HER2 therapies.

Last year, Immutep chief executive officer Mark Voigt said the Aipac trial combined IMP321, or eftilagimod alpha, with paclitaxel, marketed by Bristol-Myers Squibb as Taxol (BD: May3, 2018).

Today, the company said the primary endpoint of the Aipac study was progression-free survival according to response evaluation criteria in solid tumors as evaluated by blinded independent readers.

Immutep said secondary endpoints included progression-free survival, overall response rate and overall survival.

The company said it expected to report the results by April 2020.

Immutep fell 0.1 cents or 3.8 percent to 2.55 cents with 8.5 million shares traded.

ALTHEA GROUP

Althea says it will launch Project Twenty21, a 20,000-patient, UK medical marijuana pilot study with London's Drug Science on July 18, 2019.

In May, Althea said it had a partnership with the Drug Science independent scientific committee to launch its Concierge marijuana prescription platform, to streamline the prescription process and facilitate patient referrals from primary care doctors to Althea UK prescribers (BD: May 31, 2019).

Today, Althea said it would further its partnership with Drug Science "with the goal of increasing the number of patients that can be prescribed medical cannabis in the UK".

The company said the pilot study would recruit patients with conditions that had been unsuccessfully treated by conventional medicine including chronic pain, post-traumatic stress disorder, anxiety, multiple sclerosis and Tourette's syndrome.

Althea said the study would collect data for "efficacy, safety, [quality of life] and patient-reported outcomes of medical cannabis use".

The company said the data would "then be used to support applications to health authorities in the expectation that there will soon be a new regulatory system for medical cannabis in the UK".

Althea said it would enrol and treat patients through My Cannabis Access Clinics in locations including London, Bristol and Glasgow.

The company said it aimed to complete enrolment by December 31, 2021.

Althea was up 7.5 cents or 7.5 percent to \$1.08 with 3.1 million shares traded.

ANTEO DIAGNOSTICS

Anteo says it has an agreement with the Madrid-based Silicio Ferrosolar for the integration of silicon into anodes for lithium ion batteries.

Anteo said it was commercializing molecular adhesives for the life sciences, diagnostics, and medical device markets.

The company said that through the agreement with the subsidiary of London's Ferroglobe Plc it had secured "access to high quality silicon materials" to continue the development and commercialization of its silicon composites for lithium ion batteries.

Anteo was unchanged at 1.3 cents with 3.7 million shares traded.

FACTOR THERAPEUTICS

Factor says it has received a second board spill call from investors including those who lost the March board spill vote.

Factor said it had received a Notice under Section 249D of the Corporations Act 2001 requesting a meeting from Richsham Nominees Pty Ltd, DC & PC Holdings Pty Ltd, Alitime Nominees Pty Ltd and Pamela Christine Neesham.

The company said that the notice called for the removal of chair Dr Cherrell Hirst and directors Dr Christian Behrenbruch, John Michailidis and Dr David Brookes; and the appointment of Darren Paul Olsen, Joshua John Wellisch and Shaun Menezes as directors.

In February, Factor said it received a board spill request to replace chair Dr Cherrell Hirst and directors Tim Hughes and John Michailidis with Bruce Lane and David Sanders (BD: Feb 5, 2019).

A substantial shareholder notice signed by David Grant Sanders as “director of substantial shareholders” the Abu Dhabi-based Steven Scott Day and the Perth, Western Australia based Pura Vida, Freshero, and Canadian Nickel Corp said they had become substantial shareholders in Factor.

On February 7, the group added three more Perth-based names, Alitime Nominees Pty Ltd for the Honeyham Family, David Charles Neesham and Pamela Christine Neesham, with a total of 155,078,397 shares or 14.87 percent (BD: Feb 7, 2019).

On March 21, ahead of the spill call extraordinary general meeting the combined dissident shareholding was 208,183,121 shares or 19.97 percent (BD: Mar 21, 2019).

The following week, Factor Therapeutics said the spill resolution had failed, narrowly, but the company earned a remuneration report first strike, with 42.7 percent of votes against (BD: Mar 27, 2019).

The company said that the resolution to appoint Mr Lane and Mr Sanders failed with about 57 percent against and about 43 percent in favor, along with the same numbers in support of Dr Hirst, Mr Hughes and Mr Michailidis.

Factor’s most recent Appendix 3B new issue announcement said the company had 1,042,835,633 shares on issue, meaning the largest number of votes against the company, 314,182,410 against the placement capacity amounted to 30.1 percent of the shares on issue, sufficient to requisition extraordinary general meetings.

Following the failed spill meeting, the group reduced to 129,183,121 shares or 12.39 percent and last month increased their holding to 149,183,121 shares or 14.31 percent (BD: Mar 29, May 2, 2019).

Last year, Factor fell as much as 97.3 percent on news that its 157-patient phase II trial of VF001 for venous leg ulcers “failed to meet all endpoints” (BD: Nov 14, 2018).

Today, a new group, comprising the Perth-based Alitime Nominees for the Honeyham Family, along with the Attadale, Western Australia-based Ms Meesham, DC & PC Holdings for the DC and PC Neesham Super account and Richsham Nominees, signed by Timothy Neesham as the director of substantial holders” said it had become substantial in Factor Therapeutics with 65,275,000 shares or 6.26 percent.

Factor fell 0.1 cents or 20 percent to 0.4 cents with 1.1 million shares traded.

IMPEDIMED

Impedimed has requested a trading halt pending “a capital raising”.

Trading will resume on June 27, 2019 or on an earlier announcement.

Impedimed last traded at 11.5 cents.

IMPEDIMED

Unisuper says it has increased its substantial holdings in Impedimed from 19,305,272 shares (5.09%) to 26,737,759 shares (7.04%).

The substantial shareholder notice filed by BNP Paribas said that between February 4 and June 18, 2019 Unisuper bought 7,432,487 shares for \$1,206,501 or an average price of 16.2 cents a share.

BNP Paribas said that on June 20, 2019 Unisuper bought 8,150,657 shares for \$3,073,980 or 37.7 cents a share, and the same number of shares was sold by Discovery Asset Management on the same day for the same price.

According to Commsec data, on June 20, Impedimed traded between 10.5 cents and 12 cents, with 3,137,617 shares traded.

ALCIDION GROUP

Alcidion says Simon Chamberlain will replace Geoffrey Rohrsheim as a non-executive director from July 1, 2019.

Alcidion said Mr Rohrsheim would step down from the board effective June 30, 2019.

The company said Mr Chamberlain was currently Medadvisor's general manager and previously was Medibank Private's general manager and prior to that was a Qantas Airways executive.

Alcidion said Mr Chamberlain held a Bachelor of Commerce and a Bachelor of Laws from Melbourne's Monash University.

Alcidion fell half a cent or 4.2 percent to 11.5 cents with 3.4 million shares traded.